Login
Home
Charts
Search
Watchlist
Products

Neochem Bio Solutions Ltd

NEOCHEM·NSE
105.000.00%Mon, 21 Sept '26

Neochem Bio Solutions Ltd

NEOCHEM
NSE
105.00
0.00%
|Mon, 21 Sept '26
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
180Cr
Close
Close Price
105.00
Industry
Industry
Chemicals - Speciality
PE
Price To Earnings
21.13
PS
Price To Sales
1.62
Revenue
Revenue
111Cr
Rev Gr TTM
Revenue Growth TTM
31.52%
PAT Gr TTM
PAT Growth TTM
61.65%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
Quarter
Revenue
RevenueCr
Growth YoY
Revenue Growth YoY%
Expenses
ExpensesCr
Operating Profit
Operating ProfitCr
OPM
OPM%
Other Income
Other IncomeCr
Interest Expense
Interest ExpenseCr
Depreciation
DepreciationCr
PBT
PBTCr
Tax
TaxCr
PAT
PATCr
Growth YoY
PAT Growth YoY%
NPM
NPM%
EPS
EPS
Quarter
Revenue
RevenueCr
Growth YoY
Revenue Growth YoY%
Expenses
ExpensesCr
Operating Profit
Operating ProfitCr
OPM
OPM%
Other Income
Other IncomeCr
Interest Expense
Interest ExpenseCr
Depreciation
DepreciationCr
PBT
PBTCr
Tax
TaxCr
PAT
PATCr
Growth YoY
PAT Growth YoY%
NPM
NPM%
EPS
EPS

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue
RevenueCr
49486184111
Growth
Revenue Growth%
-0.826.937.731.5
Expenses
ExpensesCr
4544557191
Operating Profit
Operating ProfitCr
4461320
OPM
OPM%
7.28.910.015.217.9
Other Income
Other IncomeCr
01122
Interest Expense
Interest ExpenseCr
12344
Depreciation
DepreciationCr
11111
PBT
PBTCr
1231017
Tax
TaxCr
00135
PAT
PATCr
112712
Growth
PAT Growth%
17.468.9286.161.6
NPM
NPM%
2.02.43.18.810.9
EPS
EPS
3.22.12.911.28.7
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Revenue
RevenueCr
49486184111
Growth
Revenue Growth%
-0.826.937.731.5
Expenses
ExpensesCr
4544557191
Operating Profit
Operating ProfitCr
4461320
OPM
OPM%
7.28.910.015.217.9
Other Income
Other IncomeCr
01122
Interest Expense
Interest ExpenseCr
12344
Depreciation
DepreciationCr
11111
PBT
PBTCr
1231017
Tax
TaxCr
00135
PAT
PATCr
112712
Growth
PAT Growth%
17.468.9286.161.6
NPM
NPM%
2.02.43.18.810.9
EPS
EPS
3.22.12.911.28.7

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
357717
Reserves
ReservesCr
1361362
Current Liabilities
Current LiabilitiesCr
2629324436
Non Current Liabilities
Non Current LiabilitiesCr
161319152
Total Liabilities
Total LiabilitiesCr
46516379117
Current Assets
Current AssetsCr
2932385386
Non Current Assets
Non Current AssetsCr
1719262631
Total Assets
Total AssetsCr
46516379117
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
357717
Reserves
ReservesCr
1361362
Current Liabilities
Current LiabilitiesCr
2629324436
Non Current Liabilities
Non Current LiabilitiesCr
161319152
Total Liabilities
Total LiabilitiesCr
46516379117
Current Assets
Current AssetsCr
2932385386
Non Current Assets
Non Current AssetsCr
1719262631
Total Assets
Total AssetsCr
46516379117

Cash Flow

Consolidated
Standalone
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
-1-1-12-17
Investing Cash Flow
Investing Cash FlowCr
-3-312-1-9
Financing Cash Flow
Financing Cash FlowCr
44-11-126
Net Cash Flow
Net Cash FlowCr
00000
Free Cash Flow
Free Cash FlowCr
-4-4111-19
CFO To PAT
CFO To PAT%
-150.3-85.0-33.127.4-140.8
CFO To EBITDA
CFO To EBITDA%
-41.6-22.6-10.415.9-85.3
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
-1-1-12-17
Investing Cash Flow
Investing Cash FlowCr
-3-312-1-9
Financing Cash Flow
Financing Cash FlowCr
44-11-126
Net Cash Flow
Net Cash FlowCr
00000
Free Cash Flow
Free Cash FlowCr
-4-4111-19
CFO To PAT
CFO To PAT%
-150.3-85.0-33.127.4-140.8
CFO To EBITDA
CFO To EBITDA%
-41.6-22.6-10.415.9-85.3

Ratios

Consolidated
Standalone
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
108180
Price To Earnings
Price To Earnings
9.021.1
Price To Sales
Price To Sales
1.01.6
Price To Book
Price To Book
1.42.3
EV To EBITDA
EV To EBITDA
6.3
Profitability Ratios
Profitability Ratios
GPM
GPM%
27.833.534.031.230.330.3
OPM
OPM%
7.28.910.015.217.917.9
NPM
NPM%
2.02.43.18.810.910.9
ROCE
ROCE%
9.410.712.624.321.421.4
ROE
ROE%
23.713.615.737.715.315.3
ROA
ROA%
2.12.33.09.410.310.3
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
108180
Price To Earnings
Price To Earnings
9.021.1
Price To Sales
Price To Sales
1.01.6
Price To Book
Price To Book
1.42.3
EV To EBITDA
EV To EBITDA
6.3
Profitability Ratios
Profitability Ratios
GPM
GPM%
27.833.534.031.230.330.3
OPM
OPM%
7.28.910.015.217.917.9
NPM
NPM%
2.02.43.18.810.910.9
ROCE
ROCE%
9.410.712.624.321.421.4
ROE
ROE%
23.713.615.737.715.315.3
ROA
ROA%
2.12.33.09.410.310.3
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Neochem Bio Solutions is a specialty chemical company that makes the invisible ingredients inside everyday products - the softener in your shirt, the foam in your shampoo, the smooth finish on a painted wall. It began in 1978 as a small trading firm serving Gujarat’s textile mills and spent nearly five decades transforming into a manufacturer with its own brand, its own factory, and a deliberate push beyond textiles into home and personal care. The recurring approach is to master a chemical application for one industry, build a branded formulation around it, then adapt that know-how into adjacent markets - textiles taught the company softening and finishing, and that same science now sells to paint and detergent makers. # Business segments A single specialty-chemicals engine organised into four product families - polymers, surfactants, silicones and bio-based esters - that share one factory, one R&D lab and one distribution network, selling to textile mills, soap makers and paint companies alike. ## 1. Specialty performance chemicals: a formulator that sells outcomes, not molecules **The company makes 350-plus customised chemical formulations that industrial customers pour into their own production lines to get a specific result - softer fabric, thicker paint, cleaner dishes - and nearly all of it now sells under its own brand.** - **Sold under its own label, not someone else’s** - until FY22, three-quarters of revenue came from white-label manufacturing for other brands; by FY26, over 80% of revenue carried the company’s own brand, sold through its own sales team and distributor channel, which means the customer relationship and pricing power belong to Neochem, not a middleman. - **Four product families, each a different chemical toolbox** - polymers (about 29% of FY26 revenue) provide binding, thickening and softening for textiles, paints and adhesives; surfactants (about 27%) create foam and cleaning action in shampoos, detergents and industrial cleaners; silicones (about 17%) deliver smoothness, slip and anti-foam properties; and bio-based esters (about 27%) are plant-derived softeners and cleaning agents that offer a natural hedge against crude-oil price swings because they come from vegetable sources, not petroleum. - **Stickiness comes from solving a customer’s process problem** - the company has developed specific solutions like a single-bath washing agent that replaces a traditional two-bath system, and a pre-treatment formulation that substitutes five separate chemicals, saving textile mills water, energy and time; that kind of embedded problem-solving makes it harder for a customer to switch suppliers on price alone. - **New products target import substitution and sustainability** - recent launches include a high-performance surface enhancer for paints that replaces an imported product, and a bio-based one-bath textile process that cuts water use by 25% and energy use by 20%, fitting a strategy of bringing technologies to India first as a distributor, then building volume to justify local manufacture. ## Manufacturing and R&D infrastructure **One integrated plant with nearly half its capacity still available, plus an in-house lab that turns customer needs into proprietary formulations - the physical backbone that lets the company scale without a major capital outlay.** - **22,000-tonne capacity, only half used** - the Moraiya, Ahmedabad plant produced 11,589 metric tonnes in FY26, meaning roughly 47% headroom remains within the existing facility, and management has stated no major capex is needed for the next one-and-a-half to two years. - **Formulation-driven, not continuous-process** - the manufacturing sequence runs from water charging and reactor heating through sequential raw-material addition and in-process lab testing to final quality check and packaging, a batch approach that lets the company switch between 350-plus formulations on the same equipment. - **R&D focused on three practical goals** - the on-site lab with pilot reactor and dyeing machines works on process-efficiency products that save customers time and utilities, bio-based alternatives to conventional chemicals, and import substitutes that fill gaps in the Indian market. - **Certifications that open doors** - the plant holds ISO 9001, 14001 and 45001, plus GOTS 7.0 (Global Organic Textile Standard) and ZDHC Level 3, credentials that matter to export customers and global brands auditing their supply chains. ## Distribution and international markets **A network of over 50 domestic distributors puts products into 228 Indian factories, while a small but growing export presence across 12 countries tests demand for bio-based specialties abroad.** - **Distributors carry the brand to hundreds of factories** - the company sells through more than 50 authorised distributors across India, reaching 228 domestic customers, with a 16-person in-house sales team that stays in regular contact with distributors to gather customer feedback and position products against competitors. - **Exports are small but spread wide** - about 5% of FY26 revenue came from exports to 12 countries including Bangladesh, Vietnam, Australia, Egypt and Canada, with the international approach focused on markets where the company can provide technical support and ensure regulatory compliance. - **The Lamoral partnership is a blueprint for technology access** - Neochem is the exclusive South Asian distributor for a Dutch maker of bio-based fluorine-free water and stain repellents, with an informal agreement to extend into Southeast Asia; the model is to distribute first, build volume, then transfer the technology for local manufacturing in India, the same playbook the company intends to repeat with other advanced technologies. # Group structure and partners **A promoter-led company with a board that blends chemical-industry veterans and financial oversight, plus one strategic distribution partnership that doubles as a technology pipeline.** - **Leadership with decades on the factory floor** - Managing Director Swapnil Makati has over 20 years of experience and a post-graduate diploma in chemical engineering; Whole-Time Director Hemangini Dathia holds a chemical-engineering diploma and an MBA. - **A board built for a scaling chemical company** - Chairman Dinesh Chopra spent over 25 years in sales and business development at BASF India and Honeywell India; Non-Executive Director Rajasekaran Guha is a fellow member of three professional accounting bodies and previously worked at Akzo Nobel India, bringing both audit and coatings-industry knowledge. - **One exclusive partnership, with more being explored** - the Lamoral Coatings arrangement gives Neochem exclusive distribution rights for South Asia, with an eventual path to local technology transfer once volumes justify it; the company is actively looking for similar partnerships in specialty textile colours and performance additives.

Documents — Neochem Bio Solutions Ltd

  • Q4 FY2026 Earnings Call Transcript (Mar 2026, PDF): https://www.stockscans.in/document/zfqb7ti4i46k5k18snng3967.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/rx79km90y8gexlky9vzdopz3.pdf
  • Q1 FY2027 Investor Presentation (Jun 2026, PDF): https://www.stockscans.in/document/eoapomublsqvnn6lwfp60ins.pdf
  • Q4 FY2026 Investor Presentation (Mar 2026, PDF): https://www.stockscans.in/document/idatitvipwectsxifz7i01jw.pdf
  • Q3 FY2026 Investor Presentation (Dec 2025, PDF): https://www.stockscans.in/document/hy2i15ua2gisf7axsaakzjah.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/tloko8pqp9j7bsjtiqt5tvw1.pdf

Concall Transcript Summaries — Neochem Bio Solutions Ltd

  • Q4 FY2026 Concall Transcript Summary (Mar 2026): https://www.stockscans.in/company/NSE%3ANEOCHEM/transcript-notes/202603/zfqb7ti4i46k5k18snng3967.pdf